PMC:7324763 / 55943-56298
Annnotations
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T899 | 200-207 | UBERON:0000479 | denotes | tissues |
| T96654 | 200-207 | UBERON:0000479 | denotes | tissues |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T703 | 200-207 | Body_part | denotes | tissues | http://purl.org/sig/ont/fma/fma9637 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T718 | 137-147 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
| T719 | 167-174 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signals |
| T720 | 245-248 | http://purl.obolibrary.org/obo/CLO_0054057 | denotes | 181 |
MyTest
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32655581-26812607-34771768 | 240-243 | 26812607 | denotes | 180 |
| 32655581-32527928-34771769 | 245-248 | 32527928 | denotes | 181 |
TEST0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32655581-232-239-3171341 | 240-243 | ["26812607"] | denotes | 180 |
| 32655581-233-240-3171342 | 245-248 | ["32527928"] | denotes | 181 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32655581-26812607-34771768 | 240-243 | 26812607 | denotes | 180 |
| 32655581-32527928-34771769 | 245-248 | 32527928 | denotes | 181 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T343 | 0-250 | Sentence | denotes | Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). |
| T344 | 251-355 | Sentence | denotes | For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored. |